ObsEva to present data on two clinical development programs

0


Data Phase 3 study of Yselty® (linzagolix) for the treatment of uterine fibroids to be discussed in an oral presentation; Baseline data from the Yselty pilot study for the treatment of severe adenomyosis to be present in an emailuh

Data IMPLANT 1 Phase 2 study of nolasiban for uterine contractility in IVF patients prior to embryo transfer be featured in an ePoster

GENEVA, Switzerland and BOSTON June 24, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company that develops and markets novel therapies to improve women’s reproductive health, today announced the presentation of data from two of its clinical development programs to the European Society of Human Reproduction and Embryology (ESHRE) Virtual 37e Annual meeting, to be held from June 26 to July 1, 2021.

Details of the presentations for the Yselty program are the following:

  • Title: Long-term secondary efficacy of Linzagolix for heavy menstrual bleeding (HMB) due to uterine fibroids (UF): 52-week results from two randomized phase 3 placebo-controlled trials

Format: Oral presentation followed by a question and answer session

Presenter: Hugh Taylor, MD, Professor and Chairman of the Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine

Date of the session & Time: Tuesday, June 29, 2021 at 4:15 p.m. CEST

  • Title: Efficacy and safety of Linzagolix for the treatment of severe adenomyosis: first results of a pilot study

Format: Electronic poster

Presenter: Olivier Give, MD, Ph.D., Co-founder and Co-CEO of the Institute of Breast and Gynecological Surgery in Avignon

Date of the session & Time: EPosters will be available on demand via the ESHRE conference portal on Saturday June 26 from 7:00 a.m. CEST

Details of the presentation for the nolasiban program are the following:

  • Title: The effect of Nolasiban on uterine contractility at the time of embryo transfer into in vitro Fertilization patients

Format: Electronic poster

Presenter: Connie Rees, MD, Obstetrics and Gynecology Researcher and Physician, Catharina Hospital

Date and time of the session: EPosters will be available on demand via the ESHRE conference portal on Saturday June 26 from 7:00 a.m. CEST

The link to the session will be available under “Calendar of Events” in the Investors section of the ObsEva website at www.ObsEva.com

About ObsEva

ObsEva is a biopharmaceutical company that develops and markets new therapies to improve reproductive health and pregnancy in women. Through strategic licensing and disciplined drug development, ObsEva has established an advanced clinical pipeline with development programs focused on the treatment of endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and trades under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it trades under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

Caution regarding forward-looking statements

Any statements in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements may be identified by words such as “believe “,” Expect “,” may “,” plan “,” potential “,” will fly “and similar phrases, and are based on current ObsEva beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of ObsEva’s product candidates, expectations regarding regulatory and development milestones, including the potential timing of regulatory submissions to the EMA and FDA, and ObsEva’s ability to obtain and maintain regulatory approvals for its product candidates, and the results of interactions with regulatory authorities. These statements involve risks and uncertainties which could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that can cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of previous clinical trials may not be predictive of the results of clinical trials. at later stages, the associated interactions with regulators, ObsEva’s dependence on third parties over which it does not always have full control, the impact of the new coronavirus epidemic and other risks and uncertainties described in the Risk Factors section of ObsEva’s annual report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission (SEC) on March 5, 2021 and other documents filed by ObsEva with the SEC. These documents are available on the Investors page of the ObsEva website at http://www.ObsEva.com. All forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation and does not intend to make up-to-date forward-looking statements. whether as a result of new information, future events or otherwise.

For more information, please contact:

CEO office contact
Shauna Dillon
[email protected]
+41 22 552 1550

Investor contact:
Joyce Allaire
[email protected]
+1 (617) -435-6602

  • ObsEva to Present Data on Two Programs at ESHRE’s 37th Virtual Annual Meeting


Share.

About Author

Leave A Reply